NovoCureBSP:N2VC34 46 PB Ratio is 0.47 as of Jun. 25, 2026, which is 97% below its 10-year median of 16.78. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, NovoCure ranks worse than 80.58% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), NovoCure's share price is R$7.08. NovoCure's Book Value per Share for the quarter that ended in Mar. 2026 was R$14.93. Hence, NovoCure's PB Ratio of today is 0.47.
The historical rank and industry rank for NovoCure's PB Ratio or its related term are showing as below:
BSP:N2VC34'
s PB Ratio Range Over the Past 10 Years
Min: 3.02 Med: 16.78 Max: 61.36
Current: 5.16
During the past 13 years, NovoCure's highest PB Ratio was 61.36. The lowest was 3.02. And the median was 16.78.
BSP:N2VC34's PB Ratio is ranked worse than 80.58% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs BSP:N2VC34: 5.16
During the past 12 months, NovoCure's average Book Value Per Share Growth Rate was -12.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -7.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NovoCure was 54.20% per year. The lowest was -26.20% per year. And the median was -1.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NovoCure PB Ratio Related Terms
NovoCure PB Ratio Historical Data
* Premium members only.
The historical data trend for NovoCure's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, ESTA, AXGN: PB Ratio Comparison
For the Medical Devices subindustry, NovoCure's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's PB Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NovoCure's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NovoCure (BSP:N2VC34) has a PB Ratio of 0.47 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NovoCure and its competitors. This is 97% below median its historical median of 16.78. Over the past decade, NovoCure's PB Ratio has ranged from 3.02 to 61.36. According to the industry distribution chart, NovoCure ranks #635 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 80.6%.
Is NovoCure's PB Ratio too high?
NovoCure's current PB Ratio of 0.47 is 97% below median its 10-year median of 16.78. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 61.36. The Medical Devices & Instruments industry median PB Ratio is 2.05. NovoCure's value of 0.47 is 77% below this industry median. Based on the distribution chart, NovoCure ranks #635 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's PB Ratio compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #635 out of 788 companies for PB Ratio. This places NovoCure in the lower half of its industry. The industry median PB Ratio is 2.05. NovoCure's value of 0.47 is 77% below this benchmark. Historically, NovoCure's own PB Ratio has ranged from 3.02 to 61.36 over the past decade. While the company's 10-year median is 16.78 vs. the industry median of 2.05, NovoCure has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovoCure's current PB Ratio of 0.47 is 77% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NovoCure and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current PB Ratio is 0.47, which is 97% below median its own 10-year median of 16.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current PB Ratio is 0.47, which is 97% below median its 10-year median of 16.78 and 77% below the Medical Devices & Instruments industry median of 2.05. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current PB Ratio is 0.47 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for BSP:N2VC34:
PB Ratio: 0.47 (97% below median its 10-year median of 16.78)
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
Industry Position: 77% below the Medical Devices & Instruments median (#635 of 788)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score
Get the complete analysis for BSP:N2VC34
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
